Five pediatric cancers – update on genetic implications

Current Pediatric Reviews

Volumn 13, Issue 1, 2017, Pages 42-48

  Cooper, Stacy ^a   Rubens, Jeffrey ^b   Bodurtha, Joann ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Brain tumors; Cancer; Genetics; Leukemia; Lymphoma; Pediatrics; Retinoblastoma; Wilms tumor

Indexed keywords

MOXETUMOMAB PASUDOTOX;

ASTROCYTOMA; BECKWITH WIEDEMANN SYNDROME; BRAIN TUMOR; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; CYTOGENETICS; GENETIC SCREENING; GLIOMA; HIGH RISK INFANT; HUMAN; IMMUNOTHERAPY; LEUKEMIA; LOSS OF FUNCTION MUTATION; MEDULLOBLASTOMA; MOLECULARLY TARGETED THERAPY; NEPHROBLASTOMA; NEUROFIBROMATOSIS TYPE 1; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PEDIATRICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; SOUTHERN BLOTTING; TRISOMY 21; CHILD; GENETICS; LYMPHOMA; PROCEDURES;

BRAIN NEOPLASMS; CHILD; GENETIC TESTING; HUMANS; LEUKEMIA; LYMPHOMA; MOLECULAR TARGETED THERAPY; PEDIATRICS; RETINOBLASTOMA; WILMS TUMOR;

EID: 85020553203     PISSN: 15733963     EISSN: 18756336     Source Type: Journal    
DOI: 10.2174/1573396312666161213114223     Document Type: Review

References (62)

1. Rodriguez-Galindo C, Friedrich P, Alcasabas P, et al. Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge. J Clin Oncol 2015 Sep 20; 33(27): 3065-73.
2. Gupta S, Howard SC, Hunger SP, et al. Treating Childhood Cancer in Low-and Middle-Income Countries. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC): The International Bank for Reconstruction and Development/The World Bank; 2015 Nov 01. Chapter 7.
3. Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 2015 Dec 10; 373(24): 2336-46.
4. Schmiegelow K. Treatment-related toxicities in children with acute lymphoblastic leukaemia predisposition syndromes. Eur J Med Genet 2016 Feb 11. pii: S1769-7212(16)30024-6.
5. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary Brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014; 16(s5): iv1-iv63.
6. Packer RJ, Rorke-Adams LB, Lau CC, et al.: Embryonal and pineal region tumors. In: Pizzo PA, Poplack DG, eds.: Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams and Wilkins, 2011, pp 772-808.
7. Penman CL, Faulkner C, Lowis S, Kurian KM. Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas. Frontiers in Oncology 2015; 5(54): 1-8.
8. Johnson KJ, Cullen J, Barnholtz-Sloan JS, Ostrom QT, Langer CE, Turner MC, et al. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomarkers Prev 2014; 23(12): 2716-36.
9. Freeman CR, Farmer JP, Montes J. Low grade astrocytomas in children: evolving management strategies. Int J Radiat Oncol Biol Phys 1998; 41: 979-87.
10. Campbell JW, Pollack IF. Cerebellar astrocytomas in children. J Neurooncol 1996; 28: 223-31.
11. Gajjar A, Safford RA, Heideman R, et al. Low-grade astrocytoma: a decade of experience at St. Jude Children’s Research Hospital. J Clin Oncol 1997; 15: 2792-9.
12. Garre ML, Cama A, Bagnasco F, et al. Medulloblastoma variants: age dependent occurrence and relation to Gorlin syndrome – a new clinical perspective. Clin Cancer Res 2009; 15(7): 2463-71.
13. Gajjar A, Bowers C, Karajannis MA, et al. Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol Sept 20, 2015; 33(27): 2986-98.
14. Varan A, Sen H, Aydin B, et al. Neurofibromatosis type 1 and malignancy in childhood. Clin Genet Mar 2016; 89(3): 341-5.
15. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012; 123(4): 465-72.
16. Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol 2015; 33(24): 2646-2654.
17. Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 2011; 121(1): 148-60.
18. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell 2010; 17(4): 388-99.
19. Wilhelm SM, Careter C, Tang LY, et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099-109.
20. Karajannis MA, Legault G, Fisher MJ, et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol 2014; 16(10): 1408-16.
21. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008; 105(8): 3041-6.
22. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature (2006) 439(7074): 358-62.
23. Howlader N, Noone AM, Krapcho M, et al., eds.: Childhood Cancer SEER Cancer Statistics Review, 1975-2010. Bethesda, Md: National Cancer Institute, 2013, Section 28.
24. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009; 113(12): 2619-2628.
25. Seif AE. Pediatric leukemia predisposition syndromes: Clues to understanding leukemogenesis. Cancer Genetics 2011; 204(5): 227-244.
26. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008; 35(4): 418-29.
27. Schultz KR, Devidas M, Bowman WP et al. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031. Leukemia 2014; 28(4): 964-7.
28. Annesley CE, Brown P. Leukemia. Ther Adv Hematol 2015; 6(2): 61-79.
29. Gaynon PS, A.L. Angiolillo, W.L. Carroll, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children’s Oncology Group Report. Leukemia 2010; 24 (2): 285-97.
30. Gamis AS, T.A. Alonzo, J.P. Perentesis, et al. Children’s Oncology Group’s 2013 blueprint for research: acute myeloid leukemia. Pediatr Blood Cancer 2012; 60 (6): 964-71.
31. Goldin LR, Björkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146 (1): 91.
32. Shapiro RS. Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists. Am J Hematol 2011; 86 (1): 48.
33. Poppema S, Kaleta J, Hepperle B. Chromosomal abnormalities in patients with Hodgkin’s disease: evidence for frequent involvement of the 14q chromosomal region but infrequent bcl-2 gene rearrangement in Reed-Sternberg cells. J Natl Cancer Inst 1992; 84 (23): 1789-93.
34. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206 (5): 981-9.
35. Otto C, Giefing M, Massow A, et al. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br J Haematol 2012; 157(6): 702-8.
36. Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L and Reiter A: Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 2009; 27(6): 897-903.
37. Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I, d’Amore ES, Reiter A, Woessmann W, Rosolen A. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2014; 123(3): 334-7.
38. Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, Campana D. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children’s oncology group. J Clin Oncol 2009; 27(21): 3533-9.
39. Mayes S, Brown N, Illidge TM. New antibody drug treatments for lymphoma. Expert Opin Biol Ther 2011; 11(5): 623-40.
40. Meinhardt A, Burkhardt B, Zimmermann M et al. Phase II window study on rituximab in newly diagnosed pediatric mature B cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol 2010; 28 (19): 3115-21.
41. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379-91.
42. Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 2013; 14(6): 472-80.
43. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30(18): 2183-9.
44. Pro B, Advani R, Brice P et al. http://www.ncbi.nlm.nih.gov/pubmed/22614995 Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30(18): 2190-6.
45. Burkhardt B, Zimmermann M, Oschlies I, et al.: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005; 131 (1): 39-49.
46. Rodriguez-Galindo C, Orbach DB, VanderVeen D. Retinoblastoma. Pediatr Clin N Am 2015; 62: 2101-223.
47. Beck-Popovic M, Balmer A, Maeder P, et al. Benign pineal cysts in children with bilateral retinoblastoma: a new variant of trilateral retinoblastoma? Pediatr Blood Cancer 2006; 46: 755-61.
48. Draper GJ, Sanders BM, Brownhill PA, et al. Patterns of risk of hereditary retinoblastoma and applications to genetic counseling. Br J Cancer 1992; 66: 211-9.
49. Lohmann DR, Gallie BL. Retinoblastoma. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2000 [updated 2013 Mar 28].
50. Ghassemi F, Khodabande A. Risk definition and management strategies in retinoblastoma: current perspectives. Clin Ophthalmol. 2015; 9: 985-94.
51. Francis J, Gobin Y, Dunkel I et al. Carboplatin 1/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. PLoS One 2013; 8: e72441.
52. Dunkel IJ, Khakoo Y, Kernan NA et al. Intensive ultimodality therapy for patients with stage 4ametastatic retinoblastoma. Pediatr blood Cancer 2010; 55: 55-9.
53. Houston SK, Lampidis TJ, Murray TG. Models and discovery strategies for new therapies of retinoblastoma. Expert Opin Drug Discov 2013; 8(4): 383-94.
54. Pritchard EM, Dyer MA, Guy RK. Progress in small molecule therapeutics for the treatment of retinoblastoma. Mini Rev Med Chem. 2016; 16(6): 430-54.
55. Laurent VE, Sampor C, Solernou V, et al. Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthesis mRNA. Eur J Cancer 2013; 49: 2892-99.
56. Shinohara ET, DeWees T, Perkins SM. Subsequent malignancies and their effect on survival in patients with retinoblastoma. Pediatr Blood Cancer 2014; 61; 116-19.
57. Chen R, Liu S, Ye H, et al. Association of p53 rs1042522, MDM2 rs2279744, and p21 rs1801270 polymorphisms with retinoblastoma risk and invasion in a Chinese population. Sci Rep. 2015 Aug 20; 5: 13300.
58. Kooi IE, Mol BM, Moll AC et al. Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression. EBioMedicine 2015; 2(7): 660-70.
59. Al-Hussain T, Ali A, Akhtar M. Wilms tumor: An update. Adv Anat Pathol 2014; 21(3): 166-73.
60. Lingstedt I, Lindgren MA, Anderson E et al. The WT1 gene - its role in tumourigenesis and prospects for immunotherapeutic advances. In vivo 2014; 28: 675-82.
61. Adams DJ, Clark DA. Common genetic and epigenetic syndromes. Pediatri Clin N Am 2015; 62: 411-26.
62. Israels T, Callinor J, Howard S, Arra RH. Treating children with cancer worldwide - challenges and interventions. Pes 2015; 136: 607-8.